Literature DB >> 8976739

Risk factors for residual and recurrent and metastatic uveal melanoma after trans-scleral local resection.

W A Manschot.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8976739      PMCID： PMC505689          DOI： 10.1136/bjo.80.11.1028

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  8 in total

1.  Impact of enucleation for choroidal melanoma on the performance of vision-dependent activities.

Authors:  M G Edwards; A P Schachat
Journal:  Arch Ophthalmol       Date:  1991-04

2.  Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

Review 3.  Uveal melanoma: therapeutic consequences of doubling times and irradiation results; a review.

Authors:  W A Manschot; R van Strik
Journal:  Int Ophthalmol       Date:  1992-03       Impact factor: 2.031

Review 4.  The treatment of primary intraocular malignancy.

Authors:  L W Brady; A M Markoe; B E Amendola; U L Karlsson; B Micaily; J A Shields; J J Augsburger
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-12       Impact factor: 7.038

5.  Risk factors for metastatic uveal melanoma after trans-scleral local resection.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

6.  Late recurrence of malignant melanoma. Analysis of 168 patients.

Authors:  N J Crowley; H F Seigler
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969

7.  Visual function following enucleation or episcleral plaque radiotherapy for posterior uveal melanoma.

Authors:  J J Augsburger; S D Goel
Journal:  Arch Ophthalmol       Date:  1994-06

8.  Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943--1952.

Authors:  O A Jensen
Journal:  Acta Ophthalmol (Copenh)       Date:  1982-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.